Emergence of NGS-based approaches has boosted the potential use of liquid biopsies for mutation detection in several genes used as cancer biomarkers, such as EGFR and ALK, allowing the establishment of guidelines in targeted therapies using TKIs in NSCLC. This evidence concerns the gene ALK and cancer.